These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32586937)

  • 1. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
    Zamarin D; Hamid O; Nayak-Kapoor A; Sahebjam S; Sznol M; Collaku A; Fox FE; Marshall MA; Hong DS
    Clin Cancer Res; 2020 Sep; 26(17):4531-4541. PubMed ID: 32586937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
    Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
    Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
    Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
    Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
    J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
    Hong DS; Rixe O; Chiu VK; Forde PM; Dragovich T; Lou Y; Nayak-Kapoor A; Leidner R; Atkins JN; Collaku A; Fox FE; Marshall MA; Olszanski AJ
    Clin Cancer Res; 2022 Feb; 28(3):479-488. PubMed ID: 34753777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
    Goldman JW; Piha-Paul SA; Curti B; Pedersen KS; Bauer TM; Groenland SL; Carvajal RD; Chhaya V; Kirby G; McGlinchey K; Hammond SA; Streicher K; Townsley DM; Chae YK; Voortman J; Marabelle A; Powderly J
    Clin Cancer Res; 2022 Sep; 28(17):3709-3719. PubMed ID: 35699623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis.
    Wang BC; Li PC; Fan JQ; Lin GH; Liu Q
    Medicine (Baltimore); 2020 Jul; 99(28):e21273. PubMed ID: 32664183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
    Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
    Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
    Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Fujiwara Y; Takahashi Y; Okada M; Kishimoto T; Kondo S; Fujikawa K; Hayama M; Sugeno M; Ueda S; Komuro K; Lanasa M; Nakano T
    Oncologist; 2022 Sep; 27(9):e703-e722. PubMed ID: 35671201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
    Algazi A; Papadopoulos KP; Tsai F; Hansen AR; Angra N; Das M; Sheth S; Siu LL
    ESMO Open; 2024 Aug; 9(8):103646. PubMed ID: 39043009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
    Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.